The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review

The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review

Bibliographic Details
Main Authors:	J. Dinnes, C. Cave, S. Huang, K. Major, R. Milne
Format:	Article
Language:	English
Published:	NIHR Journals Library 2001-01-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta5130

Similar Items

Progress of temozolomide in the treatment of recurrent high-grade gliomas
by: Jin-duo LI, et al.
Published: (2013-12-01)

The strategy for enhancing temozolomide against malignant glioma
by: Mitsutoshi eNakada, et al.
Published: (2012-08-01)

Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01)

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation
by: R Garside, et al.
Published: (2007-11-01)

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
by: Yurong Li, et al.
Published: (2023-08-01)

Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
by: Michael T. C. Poon, et al.
Published: (2021-11-01)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
by: Qunying Yang, et al.
Published: (2021-12-01)

Temozolomide and oral etoposide in children with recurrent malignant brain tumors
by: Antonio Ruggiero, et al.
Published: (2020-06-01)

β-elemene combined with temozolomide in treatment of brain glioma
by: Xiaomin Zhang, et al.
Published: (2021-12-01)

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris®) for the treatment of severe sepsis in adults: a systematic review and economic evaluation
by: C Green, et al.
Published: (2005-03-01)

Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines
by: Andrea Salmaggi, et al.
Published: (2021-05-01)

Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications
by: Bernd Kaina
Published: (2023-11-01)

MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces their chemoresistance to temozolomide
by: Rui Chen, et al.
Published: (2016-06-01)

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
by: Arai Hajime, et al.
Published: (2007-08-01)

Effect of temozolomide and methylprednisolone on the radiosensitivity in radiotherapy of human brain glioma cells
by: Yu LI, et al.
Published: (2011-06-01)

Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines
by: Nina Simona Tresch, et al.
Published: (2021-11-01)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
by: Shigeo Ohba, et al.
Published: (2021-05-01)

CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis
by: Lucio De Maria, et al.
Published: (2021-03-01)

Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment
by: Marion Rabé, et al.
Published: (2022-05-01)

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
by: Haoyue Xu, et al.
Published: (2023-12-01)

Temozolomide and chloroquine co-loaded mesoporous silica nanoparticles are effective against glioma
by: Peng Zhang, et al.
Published: (2023-08-01)

Difference in the Inhibitory Effect of Temozolomide on TJ905 Glioma Cells and Stem Cells
by: Feng Jin, et al.
Published: (2017-09-01)

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis
by: Zhifang Hu, et al.
Published: (2020-06-01)

Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment
by: Adrian Zając, et al.
Published: (2021-05-01)

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
by: Shi H, et al.
Published: (2020-05-01)

Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
by: Radu O Minea, et al.
Published: (2020-01-01)

Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
by: Patrick Beauchesne
Published: (2012-02-01)

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma
by: Vince Giles H, et al.
Published: (2005-05-01)

Elucidating cytotoxic effects of quercus infectoria gall extract on temozolomide-resistant glioma cells
by: Muhamad, Norhazilah
Published: (2023)

SU4312 Represses Glioma Progression by Inhibiting YAP and Inducing Sensitization to the Effect of Temozolomide
by: Xu Wang, et al.
Published: (2022-08-01)

Temozolomide arrests glioma growth and normalizes intratumoral extracellular pH
by: Jyotsna U. Rao, et al.
Published: (2017-08-01)

Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma
by: Qiuyun Yuan, et al.
Published: (2021-01-01)

Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells
by: Jui-Chieh Chen, et al.
Published: (2019-08-01)

A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
by: Anna-Maria Barciszewska, et al.
Published: (2015-01-01)

Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis
by: Lu Yicheng, et al.
Published: (2010-06-01)

Study on synergistic effect of Rac1 inhibitor and temozolomide in inhibiting proliferation and invasiveness of glioma cells in vitro
by: Xiao-yong HAN, et al.
Published: (2016-08-01)

Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas
by: Arsela Prelaj, et al.
Published: (2018-04-01)

Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells
by: Chung-Ching Chio, et al.
Published: (2018-04-01)

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation.
by: Bryant, J, et al.
Published: (2002)

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation
by: J. Bryant, et al.
Published: (2002-01-01)